

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 79618

**Title:** Metabolic associated fatty liver disease: The new nomenclature and approach with the hot debate

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06060788

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** Singapore

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-08-29

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-11-04 10:47

**Reviewer performed review:** 2022-11-04 15:48

**Review time:** 5 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

## **SPECIFIC COMMENTS TO AUTHORS**

This manuscript proposes to push for a change in nomenclature of "NAFLD" to MAFLD", as the clinical criteria for "MAFLD" more readily predicts for patients at high risk of complications. The manuscript summarizes organizations that support this nomenclature, but does not provide rationale for groups that do not support this change. It is unclear if the term "MAFLD" would exclude some patients with fatty liver, who might have milder disease, and if such patients should be concerned about the condition of their liver. The acceptance of the term "MAFLD" only in specific regions may segregate groups of clinicians and scientists, complicating communications. Thus the underlying definitions for these terms and consequences of acknowledging 1 or both terms only in specific regions need to be very clear.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 79618

**Title:** Metabolic associated fatty liver disease: The new nomenclature and approach with the hot debate

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05851552

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Reviewer\_Country

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-08-29

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-11-07 09:55

**Reviewer performed review:** 2022-11-07 10:33

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

The authors highlight the endorsement of the new name by different societies and groups and the outcome of different studies on the new nomenclature in addition to a short discussion of the debate arisen by some experts. Non-alcoholic fatty liver disease and Metabolic associated fatty liver disease are not explain and their mechanism is not discussed detailed. The main topic is not explain very well. NAFLD and MAFLD are should be explained in detail. For example; the author said that Eslam et al paper a new name changing the traditional NAFLD to MAFLD. Which factors were discussed by Eslam et al?

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 79618

**Title:** Metabolic associated fatty liver disease: The new nomenclature and approach with the hot debate

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04015916

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-08-29

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-11-07 01:06

**Reviewer performed review:** 2022-11-10 02:05

**Review time:** 3 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

Peer-reviewer statements	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

The modification of any disease name needs sufficient evidence based on evidence-based medicine and the support of a large number of direct clinical evidence. To replace NAFLD with MAFLD, it is necessary to provide more in-depth and extensive clinical data, such as the latest diagnostic criteria, treatment plan, drugs, judgment of results, outcome and prognosis, etc. adopted according to the progress of science and technology. There are forerunners in every era, and their behavior may not be perfect.